Jeffrey Edwards
Director/Board Member at FIBROGEN, INC.
Net worth: 324 099 $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Pyott | M | 70 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA.
Serica Technologies, Inc.
 Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | 26 years |
| James Schoeneck | M | 66 | 14 years | |
| George Lasezkay | M | 72 | 21 years | |
| William Humphries | M | 57 | 21 years | |
| David I. Stirling | M | - |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 17 years |
| Norman Schwartz | M | 74 | 35 years | |
| Arnold A. Pinkston | M | 65 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 13 years |
| James Hall | M | 61 | 7 years | |
| Clay Thorp | M | 55 | 12 years | |
| Craig Barbarosh | M | 57 | 5 years | |
| Matthew Joseph Maletta | M | 52 |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | - |
| F. Ball | M | 68 |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | 17 years |
| Christy Shaffer | M | 66 | 12 years | |
| Raymond Diradoorian | M | 66 | 37 years | |
| Gregory Hinckley | M | 77 | 41 years | |
| Samuel Gesten | M | 62 |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | 3 years |
| Adrian Howd | M | 52 |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| John Morberg | M | 60 | 3 years | |
| Robert J. Schotzinger | M | 63 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 13 years |
| Thane Wettig | M | 59 | 4 years | |
| Philippe Drouet | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 3 years |
| Andrew von Eschenbach | M | 82 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 13 years |
| Melinda Litherland | F | 66 | 7 years | |
| Suzanne Blaug | F | 66 | 5 years | |
| Timothy Ernst | M | 64 | 8 years | |
| Nancy Miller-Rich | F | 65 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 3 years |
| Aoife Brennan | M | 48 | 4 years | |
| Meichiel Keenan | F | - | 20 years | |
| Allison Schwartz | F | 43 | 8 years | |
| Nancy Hutson | M | 74 | 4 years | |
| Nelson Obus | M | 77 | 6 years | |
| Richard Croarkin | M | 69 | 8 years | |
| May Kin Ho | M | 71 | 6 years | |
| Alice Schwartz | F | 97 | 72 years | |
| Katrina Houde | F | 66 | 5 years | |
| Jeffrey Henderson | M | 59 | 9 years | |
| Joshua Schechter | M | 51 | 4 years | |
| Douglas Reed | M | 70 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 17 years |
| Gerald Lema | M | 63 | 7 years | |
| Benjamin Yerxa | M | 58 | 2 years | |
| Philip R. Tracy | M | 81 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 9 years |
| Benjamin Cravatt | M | 54 | 4 years | |
| S. Torres | M | 61 |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | 13 years |
| Rajeev Dadoo | M | 54 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | - |
| Christine Chung L. | F | 56 | 17 years | |
| Steve Laninga | M | - | 4 years | |
| Rahul Rajan Kaushik | M | - | - | |
| Andrew Stapleton | M | 68 | - | |
| Theodore J. Theophilos | M | 70 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Viral Kansara | M | - | 6 years | |
| Charles Deignan | M | 59 | 12 years | |
| Kipling Thacker | M | 69 | 14 years | |
| Barbara H. Bauschka | F | - | 8 years | |
| Jonathan Seaton | M | 53 | - | |
| Steve D. Weinstein | M | - |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | - |
| Elias Kouchakji | M | 67 | 10 years | |
| Kyle W. H. Chan | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 17 years |
| Louis J. DeGennaro | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | - |
| Dennis Dougherty | M | 76 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| David DeLucia | M | - | - | |
| Michael Crowley | M | 62 | 26 years | |
| Rafael V. Andino | M | - | 11 years | |
| Scott Collins | M | - | 7 years | |
| Leanne C. Price | F | - | 25 years | |
| Edward Chung | M | - | - | |
| Michael D. Lowenstein | M | - | 21 years | |
| Al Y. Lin | M | - | 25 years | |
| Jackie Klecker | F | - | 14 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Ingram | M | 61 | 19 years | |
| Daniel H. White | M | 57 | 8 years | |
| Albert Bolles | M | 66 | 8 years | |
| Rory Riggs | M | 71 | 29 years | |
| Brian McLaughlin | M | - | 1 years | |
| Vivid Sehgal | M | 56 | 8 years | |
| Andrew Powell | M | 66 | 4 years | |
| Leslie B. Zacks | M | 55 | 4 years | |
| Herb Boyer | M | 87 | 19 years | |
| Julian N. Stern | M | 99 | 25 years | |
| Thomas Kearns | M | 87 | 26 years | |
| Robert Williamson | M | 58 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 1 years |
| Timothy Nelson | M | 60 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | 8 years |
| Ambrose Bailey | M | 60 | - | |
| Thomas Byron Neff | M | 69 | 26 years | |
| Catherine Sohn | M | 71 | 10 years | |
| Joel McComb | M | 59 | 3 years | |
| Debbie Carosella | F | 67 | 5 years | |
| Pat Cotroneo | M | 60 | 21 years | |
| Patricio Miguel Madero Blasquez | M | 74 | 20 years | |
| Toshinari Tamura | M | 80 | 12 years | |
| Kalevi Kurkijärvi | M | 72 | 25 years | |
| Tonia Pankopf | F | 56 | 10 years | |
| Louis T. Rosso | M | - | 16 years | |
| Robert M. Malchione | M | 66 | 3 years | |
| John Goetz | M | 73 | 18 years | |
| Deborah Neff | F | 71 | 6 years | |
| Roberto Pedro Rosenkranz | M | 74 | 10 years | |
| Louis C. Drapeau | M | 79 | 10 years | |
| Diane Dahowski | F | - | 25 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 100.00% |
| Belgium | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeffrey Edwards
- Personal Network
